On July 30, 2021, the results of the phase 3 clinical trial stop-covid (nct04469114) of oral JAK inhibitor tofacitinib in the treatment of covid-19 pneumonia inpatients were published in the International Medical Journal New England Journal of Medicine (NEJM).
ວັນທີ 30 ກໍລະກົດ 2021, ຜົນຂອງການທົດລອງທາງຄລີນິກໄລຍະ 3 STOP-COVID (NCT04469114) ປະເມີນຢາ JAK inhibitor tofacitinib ສໍາລັບໃຊ້ໃນການປິ່ນປົວຄົນເຈັບທີ່ເຂົ້າໂຮງwithໍດ້ວຍໂຣກປອດບວມເນື່ອງຈາກ COVID-19 ໄດ້ຖືກຕີພິມລົງໃນວາລະສານການແພດສາກົນ" New England Journal ຂອງຢາ " (NEJM).